Electroacupuncture modulates myocardial insulin signaling and inflammatory markers in a rat model of type 2 diabetes

Abstract

Objective:

To evaluate the effects of electroacupuncture (EA) on myocardial insulin resistance (IR) in Zucker diabetic fatty (ZDF) rats, an established model for type 2 diabetes mellitus (T2DM).

Methods:

Twenty-four ZDF-Lepr^fa/fa rats were randomized to: (1) ZDF group (n = 8); (2) ZDF + PIO (pioglitazone) group (n = 8); and (3) ZDF + EA group (n = 8). An additional control group of eight healthy ZDF^+/fa rats was included (Lean group). We examined protein and mRNA expression levels of critical insulin signaling pathway intermediates including insulin receptor substrate (IRS)-1, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), adenosine monophosphate (AMP)-activated protein kinase (AMPK), ribosomal protein S6 kinase (p70S6K), glycogen synthase kinase 3β (GSK3β) and glucose transporter type 4 (GLUT4), as well as serum levels of interleukin (IL)-6, tumor necrosis factor (TNF)-α and C-reactive protein. Echocardiography and cardiac histology were performed.

Results:

Significant improvements in glucose metabolism, reflected in reduced fasting insulin levels and fasting blood glucose levels, were demonstrated after EA and PIO treatment. EA treatment also led to a notable decrease in inflammatory cytokine levels. In addition, there were marked improvements in myocardial structural integrity, as evidenced by histological analyses. Moreover, increased GLUT4 expression in myocardial tissue suggested improved insulin signaling, further supported by reductions in markers of myocardial injury such as serum troponin T type 2 (TNNT2) and B-type natriuretic peptide (BNP).

Conclusion:

EA ameliorated myocardial IR in a rat model of T2DM and positively impacted TNNT2 and BNP levels, as well as phosphorylation status and mRNA expression of several genes involved in the insulin signaling pathway. Our findings underscore the potential of EA to modulate multiple therapeutic targets in the treatment of myocardial IR. If these effects can be replicated clinically, EA may represent a promising non-pharmacological option for the management of cardiometabolic risks associated with diabetes.

Keywords

acupuncture complementary medicine diabetes diabetes and endocrinology electroacupuncture endocrinology internal medicine

Get full access to this article

View all access options for this article.

References

GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 2023; 402(10397): 203–234.

Ceriello

Postprandial hyperglycemia and diabetes complications: is it time to treat?

Diabetes 2005; 54(1): 1–7.

Gray

Kim

JK.

New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 2011; 22(10): 394–403.

Patel

Rawal

Bagchi

, et al Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev 2016; 21(1): 11–23.

Hernandez

Usmani

Rajamanickam

, et al Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11(2): 115–128.

Nassif

Kosiborod

A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. Am J Cardiol 2019; 124 Suppl 1: S12–S19.

Gilbert

Krum

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015; 385(9982): 2107–2117.

Singh

Loke

Furberg

CD.

Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30(8): 2148–2153.

Abel

O’Shea

Ramasamy

Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 2012; 32(9): 2068–2076.

10.

Dirkx

Schwenk

Glatz

, et al High fat diet induced diabetic cardiomyopathy. Prostaglandins Leukot Essent Fatty Acids 2011; 85(5): 219–225.

11.

Bertrand

Horman

Beauloye

, et al Insulin signaling in the heart. Cardiovasc Res 2008; 79(2): 238–248.

12.

Wellen

Hotamisligil

GS.

Inflammation, stress, and diabetes. J Clin Invest 2005; 115(5): 1111–1119.

13.

Zhang

Jung

, et al Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009; 58(11): 2536–2546.

14.

White

Kahn

CR.

The insulin signaling system. J Biol Chem 1994; 269(1): 1–4.

15.

Shao

Tian

Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol 2015; 6(1): 331–351.

16.

Muniyappa

Montagnani

Koh

, et al Cardiovascular actions of insulin. Endocr Rev 2007; 28(5): 463–491.

17.

Kim

Dyck

JR.

Is AMPK the savior of the failing heart?

Trends Endocrinol Metab 2015; 26(1): 40–48.

18.

Ding

Zhou

Ling

, et al Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics 2021; 11(19): 9376–9396.

19.

Liao

, et al Effects of electroacupuncture and Chinese kidney-nourishing medicine on polycystic ovary syndrome in obese patients. J Tradit Chin Med 2013; 33(3): 287–293.

20.

Firouzjaei

Wang

, et al Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr Diabetes 2016; 6(5): e209.

21.

Dong

Wang

, et al Impact of low frequency electro-acupuncture on glucose and lipid metabolism in unmarried PCOS women: a randomized controlled trial. Chin J Integr Med 2021; 27(10): 737–743.

22.

Ding

Teng

Zhu

, et al Electroacupuncture treatment ameliorates metabolic disorders in obese ZDF rats by regulating liver energy metabolism and gut microbiota. Front Endocrinol 2023; 14: 1207574.

23.

Lee

Jiu

Hsieh

CL.

Metabolism modulation in rat tissues in response to point specificity of electroacupuncture. Sci Rep 2022; 12(1): 210.

24.

Cao

Zhou

, et al Effects of electroacupuncture on intestinal microflora and plasma metabolites in an insulin-resistant mouse model of type 2 diabetes mellitus. Acupunct Med 2024; 42(2): 76–86.

25.

Shoelson

Lee

Goldfine

AB.

Inflammation and insulin resistance. J Clin Invest 2006; 116(7): 1793–1801.

26.

Nerla

Pitocco

Zaccardi

, et al Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes. Acta Diabetol 2010; 47 Suppl 1: 117–122.

27.

de Baat

Trinh

Ellingsgaard

, et al Physiological role of cytokines in the regulation of mammalian metabolism. Trends Immunol 2023; 44(8): 613–627.

28.

Daniele

Guardado Mendoza

Winnier

, et al The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 2014; 51(1): 123–131.

29.

Korkmaz-Icöz

Lehner

, et al Left ventricular pressure-volume measurements and myocardial gene expression profile in type 2 diabetic Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 2016; 311(4): H958–H971.

30.

Etaher

Gibbs

Saad

, et al Type-II myocardial infarction and chronic myocardial injury rates, invasive management, and 4-year mortality among consecutive patients undergoing high-sensitivity troponin T testing in the emergency department. Eur Heart J Qual Care Clin Outcomes 2020; 6(1): 41–48.

31.

Nyawo

Dludla

Mazibuko-Mbeje

, et al A systematic review exploring the significance of measuring epicardial fat thickness in correlation to B-type natriuretic peptide levels as prognostic and diagnostic markers in patients with or at risk of heart failure. Heart Fail Rev 2022; 27(2): 665–675.

32.

Rodeheffer

RJ.

Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?

J Am Coll Cardiol 2004; 44(4): 740–749.

33.

Slot

Garruti

Martin

, et al Glucose transporter (GLUT-4) is targeted to secretory granules in rat atrial cardiomyocytes. J Cell Biol 1997; 137(6): 1243–1254.

34.

Petersen

Shulman

GI.

Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev 2018; 98(4): 2133–2223.

35.

Khamzina

Veilleux

Bergeron

, et al Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005; 146(3): 1473–1481.

36.

Guo

XY.

Ischemic postconditioning regulates cardiomyocyte autophagic activity following ischemia/reperfusion injury. Mol Med Rep 2015; 12(1): 1169–1176.

37.

Hao

Zheng

Zhang

, et al Down-regulation of betatrophin enhances insulin sensitivity in type 2 diabetes mellitus through activation of the GSK-3β/PGC-1α signaling pathway. J Endocrinol Invest 2021; 44(9): 1857–1868.